Phase 2 N=37 Efficacy and Safety of Topically Applied Medical Therapy for the Treatment of Pediatric Glaucoma
Childhood Glaucoma
Primary: Percentage of Eyes With Response — 33 eyes
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=152 Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patients
Pediatric Glaucoma · Elevated IOP in Pediatric Patients · Ocular Hypertension in Pediatric Patients
Primary: Mean Change From Baseline in IOP at Month 3 — -5.4; -5.3 mmHg
Phase 3 N=139 A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study In Pediatric Subjects With Glaucoma.
Glaucoma
Primary: Reduction From Baseline in Mean IOP at Week 12, Last Observation Carried Forward (LOCF) — 5.72; 7.18 mmHg
Phase 1 N=25 Pharmacokinetic and Safety Study of Travoprost 0.004% in Pediatric Glaucoma Patients
Glaucoma · Ocular Hypertension
Primary: Maximum Observed Travoprost Free Acid Plasma Concentration (Cmax) — 0.0256; 0.0471; 0.0258; 0.0109 ng/mL
N/A N=175 Long-Term Non-Interventional Latanoprost Study
Glaucoma · Ocular Hypertension
Primary: Change From Baseline to Last Available Observation in Best Corrected Visual Acuity (BCVA) (Snellen or Equivalent) — 0.25; -0.07; 0.01; 0.04 logMar — p=0.1126
Phase 4 N=59 Use of Bevacizumab in Trabeculectomy Surgery
Glaucoma · Optic Neuropathy · Fibrosis
Primary: Intraocular Pressure — 13.9; 13.2 mm Hg — p=<0.05
Phase 3 N=60 A Study of Safety and the Local Anesthetic Effect of AG-920 Ophthalmic Solution in a Pediatric Population
Anesthesia, Local
Primary: The Proportion of Participants in Which an Eye Exam Was Able to be Performed — 30; 30 Participants
Phase 3 N=507 Safety of Brimonidine Tartrate Ophthalmic Solution in a Population of Pediatric, Adult, and Geriatric Participants
Hyperemia
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 66; 38; 44; 25 Participants
Phase 4 N=52 Earlier Intraocular Pressure Control After Ahmed Glaucoma Valve Implantation for Glaucoma
Glaucoma
Primary: Rate of Hypertensive Phase After Ahmed Valve Implantation for Glaucoma — 9; 12 participants
N/A N=906 Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study
Glaucoma · Glaucoma Suspect · Diabetic Retinopathy
Primary: Fundus Camera Images Via Telemedicine — 355; 384; 167 Participants
N/A N=4,812 A Study of Intraocular Pressure (IOP) Reduction in Newly Diagnosed Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Percentage of Patients With a Reduction in Intraocular Pressure (IOP) ≥ 5mmHg From Baseline — 75.9 Millimeters of Mercury (mmHg)
Phase 4 N=121 Glaucoma Biomarkers
Glaucoma · Healthy
Primary: Variation in Eye Pressure Between Individuals. — 11.5; 11.3; 11.0; 11.0 mmHg — p=0.0001
N/A N=16 Effect of Travoprost 0.004% on Retinal Oximetry in Primary Open Angle Glaucoma
Primary Open Angle Glaucoma
Primary: Blood Oxygenation — 60; 60; 60 percentage of oxygenation
Phase 2 N=67 Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.
Primary Open-Angle Glaucoma · Ocular Hypertension
Primary: Change From Baseline in Mean Diurnal Intra Ocular Pressure (IOP) in Study Eye at Day 14: Stage I — 25.97; 26.25; 25.90; 26.44 mmHg — p=0.028
Phase 2 N=47 Safety and Efficacy of a Drug Delivery System in Glaucoma
Open-angle Glaucoma · Ocular Hypertension
Primary: Mean Change in Intraocular Pressure at Day 1 — -4.16; -4.57; -0.60 mmHg
N/A N=900 Providing Financial Incentives to Improve Adherence to Referral Eye Care Visits
Glaucoma · Diabetic Retinopathy · Refractive Errors
Primary: Percentage of Participants That Adhere to Referral Appointment — 80; 92 Participants
Phase 4 N=35 Peripapillary Blood Flow After Use of Anti-glaucoma Medications: An OCT Angiography Study
Glaucoma; Drugs · Normal Tension Glaucoma · Primary Open-angle Glaucoma
Primary: Changes in Vessel Density in Treatment Groups Assessed by OCT Angiography — -0.51; 2.59; -0.96; 0.96 percent change
Phase 3 N=426 A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 3 Study
Glaucoma and Ocular Hypertension
Primary: Intraocular Pressure at Week 1 — 19.0; 19.1; 18.0; 18.2 mmHg
N/A N=1,553 A Study of GANFORT® UD in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) in a Medical Setting
Glaucoma, Primary Open Angle · Ocular Hypertension
Primary: Change From Baseline in Intraocular Pressure (IOP) in the Study Eye — 22.18; 16.11 mmHg
Phase 3 N=417 A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 Study
Glaucoma and Ocular Hypertension
Primary: Intraocular Pressure (IOP) at Week 1 — 19.4; 19.7; 18.5; 18.9 mmHg
N/A N=120 Comparison of Ex-PRESSTM Mini Glaucoma Shunt to Trabeculectomy in Subjects With Open Angle Glaucoma
Glaucoma
Primary: Postoperative Intraocular Pressure — 14.6; 14.7 mmHg
Phase 4 N=108 Pediatric Zylet Safety and Efficacy Study
Chalazion · Hordeolum
Primary: Treatment Emergent Adverse Events — 2; 0; 1; 1 participants
Phase 4 N=87 A Study of 0.03% Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Change From Baseline in Intraocular Pressure (IOP) in the Study Eye — 22.2; -6.7 Millimeters of Mercury (mmHg)
Phase 3 N=1,636 Ocular Hypertension Treatment Study (OHTS)
Ocular Hypertension · Glaucoma
Primary: Incidence of Primary Open-Angle Glaucoma in Hypotensive Patients — 9.5; 4.4; 20.0; 14.1 percent of participants
Phase 4 N=30 Travoprost 0.004% Versus Pilocarpine 1% in Patients With Chronic Angle Closure Glaucoma (CACG)
Angle-closure Glaucoma
Primary: Mean Intraocular Pressure (IOP) — 15.77; 18.35 millimeters mercury (mm Hg)
N/A N=358 An Observational Study of Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) Who Switched IOP-lowering Treatments
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Change From Baseline in Intraocular Pressure (IOP) in the Right Eye — -4.5 mmHg
Phase 3 N=495 To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Mean Change in Intra-ocular Pressure — -4.25; -3.80; -4.22; -4.00 mmHG
N/A N=26 MINIject in Patients With Open Angle Glaucoma Uncontrolled by Topical Hypotensive Medications
Open Angle Glaucoma
Primary: Change in Medicated Diurnal Intra-ocular Pressure (IOP) at 6 Months Post-implantation — -8.95 mmHg
Phase 2 N=298 Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular Pressure
Open Angle Glaucoma · Ocular Hypertension
Primary: Intraocular Pressure (IOP) — 25.11; 25.12; 25.35; 25.99 mmHg — p=<0.0001
Phase 2 N=70 Safety and Effects of Brimonidine Intravitreal Implant in Patients With Glaucomatous Optic Neuropathy
Glaucoma, Open-Angle
Primary: Percentage of Patients With a Visual Field Improvement in the Study Eye — 12.0; 9.5; 4.2 Percentage of Patients